Form 4: Immunovant CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Immunovant CEO Peter Salzmann sold 15,439 shares of common stock on February 19, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On February 19, 2025, Peter Salzmann, the CEO of Immunovant, Inc., sold 15,439 shares of Immunovant's common stock.
- The sale was executed to cover tax withholding obligations associated with the vesting of 28,204 restricted stock units (RSUs) on February 17, 2025.
- The shares were sold at a weighted average price of $20.86, with individual transactions ranging from $20.51 to $21.09 per share.
- Following the transaction, Salzmann beneficially owns 948,786 shares of Immunovant common stock.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sell to cover taxes) and doesn't contain information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives.
Stakeholder Impact
- The sale of shares by the CEO could have a minor, temporary impact on the stock price.
Key Dates
| Date | Description |
|---|---|
| August 17, 2022 | Holder was granted 451,264 restricted stock units (RSUs). |
| August 19, 2022 | Previous Form 4 filed reporting the grant of RSUs. |
| February 17, 2025 | 28,204 RSUs vested. |
| February 19, 2025 | Salzmann sold 15,439 shares to cover tax obligations. |
| February 21, 2025 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.